MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics
MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer clinical questions within the lung cancer continuum of care.
×
254 Results
MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer clinical questions within the lung cancer continuum of care.
A new study published in the Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell lung cancer
Biodesix announced that it has acquired Integrated Diagnostics, Inc.
The Society for Advanced Bronchoscopy (SAB) will hold its second meeting: Hot Topics in Advanced Bronchoscopy.
Biodesix announced newly published data showing the noninvasive BDX-XL2 test could reduce the number of unnecessary biopsies carried out on patients with benign nodules
Biodesix presented positive data for a blood-based test with the potential to detect a non-small cell lung cancer (NSCLC) patient’s pre-treatment risk of anti-PD-1 immunotherapy resistance
Bronchoscopy professionals in the United States need greater educational and practice-building support to ensure continued delivery of high-quality care for Americans
Researchers with Biodesix and Genentech presented findings on a test designed to predict response to atezolizumab (Tecentriq®) in patients with non-small cell lung cancer (NSCLC)
Biodesix provided an update on the Observational Registry study to evaluate the impact of BDX-XL2 on physician decision making in routine clinical use (ORACLE)
New data demonstrate that a blood-based proteomic test reliably assesses individual patient prognosis to inform treatment decisions.